FEATURESPACE
16.8.2022 16:02:11 CEST | Business Wire | Press release
Featurespace and Vital4 have signed a global partnership to provide the financial services industry with AI driven Watchlist, PEPs, Sanctions and Adverse Media screening through Featurespace’s award winning ARIC Risk Hub. With this partnership, ARIC Risk Hub for AML is a one stop, end-to-end financial crime prevention solution for the customer.
Through a single API, ARIC Risk Hub for AML will leverage the watchlist data collected and curated by Vital4 to enhance the performance of Featurespace’s self learning models, ultimately improving accuracy and reducing false positives in flagged entities and transactions. Vital4’s automated AML/ KYC data tools analyze more than 6,000 global watchlists to help identify subjects involved in sanctions, terrorism, or corruption.
“Given the complementary technologies of Featurespace and Vital4, the industry now has access to behavioral analytics coupled with sentiment analysis to truly identify the financial criminals in real time.” Said Dave Excell, Featurespace Founder.
Vital4’s AI driven system examines 13 important criteria to provide the highest levels of name-matching, removing the ambiguity of legacy systems that rely on fuzzy name matching that can miss critical data points.
“As financial crime becomes increasingly complex to combat, crossing borders and moving in real-time, AML professionals need a complete risk hub to effectively monitor and report suspicious transactions and remain compliant.” Said Amy Barbieri, Co-Founder and President of Vital4. “The risk of non-compliance has huge reputational impact, making the business case clear for technologies that improve the accuracy for anti-financial crime efforts”.
Featurespace and Vital4 are two Atlanta based AI driven technology companies led by industry leading women. The two companies are unified around a shared commitment to enable banks and financial instutions with the best technology to fight financial crime and make the world a safer place to transact.
Primary industry benefits:
AI Driven Watchlist Screening :
- Machine learning to manage increasing volume and variety of transactions and entities to screen and monitor
- Monitoring over 6,300 Watchlists and Global Sanctions in 200+ countries and regions
- Propriety entity and name matching to provide more accurate search results and reduce false positives
- Proprietary 13-point name matching algorithm – better than traditional fuzzy name matching logic
- Natural Language Processing and Sentiment Analysis to truly identify Adverse Media articles AI-powered tagging of individuals or businesses in articles
- Watchlists updated real-time
- Risk-based call-out depending on business rule logic, analytics output
Customer Screening
- Screening at onboarding, change of details and ongoing trigger-based or scheduled monitoring
- Risk-based screening policies determine depth of search
- Watchlist flags available for analysts and immediate use within rules
Real-time Transaction Screening
- Real-time enabled sanctions screening of specified transaction types (i.e. cross-border, wires, ACH)
- Screening of counterparties
- Instant responses and action tags
- Reviewed in context of wider account activity a single, intuitive UI
Featurespace continues to partner with best in class technologies to provide holistic FRAML solutions for smart thinking financial institutions. Featurespace's partnership with Vital4 provides customers with a consolidated view and ability to manage financial crime risks across AML, fraud and sanctions within a single next generation risk management platform. Featurespace’s partnership with Callsign provides Enhanced Authentication and Device ID and security is provided by Accertify, and Ciphertrace provides crypto intelligence for transactional monitoring.
About Featurespace
Featurespace is the world leader in enterprise grade technology that prevents fraud and fights financial crime. With a mission to make the world a safer place to transact, Featurespace helps banks and financial institutions protect consumers, and reduce risk and operating costs by providing industry-leading machine learning, financial crime prevention solutions. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks and is the first to profile both genuine and fraudulent behavior to identify and catch criminal activity in real time. Both are patent pending technologies that are central to Featurespace’s award winning ARIC™ Risk Hub. Over 70 direct customers and 100,000 merchants and financial institutions have put their trust in Featurespace’s technology including HSBC, NatWest, TSYS, Worldpay, Marqeta, Contis, Danske Bank, Akbank, Edenred and Permanent TSB. Founded in 2008, and headquartered in Cambridge, UK Featurespace has a team of over 400, operating globally from seven locations.
About Vital4
Vital4 is an award-winning global technology company that provides critical data to organizations for regulatory compliance and to help mitigate third-party risk. Striving to make the world a safer place, Vital4 helps identify illicit actors in the fight against financial crime, terrorism, fraud, and corruption. Vital4 was founded with four fundamental concepts in mind: compliance, accuracy, global insight, and value. The powerful search platform, Vital4Search, was built with a “tech first” approach anchored by AI and Machine learning and is the world’s fastest and most accurate proprietary data search technology on the market today. Vital4Search solves enterprise compliance problems by eliminating slow update cycles, shallow source pools and reducing the human error risk of manual legacy processes. Vital4 provides data solutions to thousands of users in banking, gaming, identity, gig economy, GRC, legal, insurance and 4 of the top 5 largest background screening companies in the world put their trust in Vital4.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220816005203/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
